ADAG - CIK 0001818838
Adagene Inc. trades as ADAG. In its fiscal 2025 annual report the company posted revenue of $7.67M, up 7332.8% from the prior year and net income of -$17.61M. This page tracks Adagene Inc. through 171 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 7 fiscal years Adagene Inc.'s revenue grew from $1.51M to $7.67M, a compound annual growth rate of 26.1%. Net profit margin expanded from -1010.2% to -229.6% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-07 |
| 6-K | - | 2026-04-17 |
| Prospectus supplement | 424B5 | 2026-04-02 |
| 6-K | - | 2026-04-02 |
| Prospectus supplement | 424B5 | 2026-04-02 |
| 6-K | - | 2026-04-02 |
| 6-K | - | 2026-04-01 |
The largest companies sharing Adagene Inc.'s SEC industry classification (pharmaceutical preparations).
Adagene Inc. reported revenue of $7.67M for fiscal year 2025, an increase of 7332.8% year over year.
In its latest fiscal year Adagene Inc. reported a net loss of $17.61M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.